CN110179937A - 一种免疫调节冲剂及制备方法 - Google Patents
一种免疫调节冲剂及制备方法 Download PDFInfo
- Publication number
- CN110179937A CN110179937A CN201910309522.2A CN201910309522A CN110179937A CN 110179937 A CN110179937 A CN 110179937A CN 201910309522 A CN201910309522 A CN 201910309522A CN 110179937 A CN110179937 A CN 110179937A
- Authority
- CN
- China
- Prior art keywords
- electuary
- immunological regulation
- hours
- water
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001900 immune effect Effects 0.000 title claims abstract description 71
- 230000033228 biological regulation Effects 0.000 title claims abstract description 70
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000007788 liquid Substances 0.000 claims abstract description 24
- 238000001914 filtration Methods 0.000 claims abstract description 21
- 241000756943 Codonopsis Species 0.000 claims abstract description 18
- 239000006228 supernatant Substances 0.000 claims abstract description 18
- 235000019441 ethanol Nutrition 0.000 claims abstract description 17
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 14
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 14
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 14
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 14
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 14
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 14
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 14
- 244000197580 Poria cocos Species 0.000 claims abstract description 14
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 14
- 239000000706 filtrate Substances 0.000 claims abstract description 14
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 13
- 235000014676 Phragmites communis Nutrition 0.000 claims abstract description 13
- 235000009566 rice Nutrition 0.000 claims abstract description 13
- 210000000582 semen Anatomy 0.000 claims abstract description 13
- 210000003038 endothelium Anatomy 0.000 claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 9
- 238000002386 leaching Methods 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 230000006837 decompression Effects 0.000 claims abstract description 6
- 238000005469 granulation Methods 0.000 claims abstract description 5
- 230000003179 granulation Effects 0.000 claims abstract description 5
- 240000007594 Oryza sativa Species 0.000 claims abstract 3
- 239000000463 material Substances 0.000 claims description 20
- 239000002994 raw material Substances 0.000 claims description 13
- 239000004576 sand Substances 0.000 claims 1
- 229940126680 traditional chinese medicines Drugs 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 abstract description 26
- 239000003814 drug Substances 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 9
- 229930006000 Sucrose Natural products 0.000 abstract description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 5
- 239000000843 powder Substances 0.000 abstract description 5
- 229960004793 sucrose Drugs 0.000 abstract description 5
- 230000029087 digestion Effects 0.000 abstract description 4
- 239000003163 gonadal steroid hormone Substances 0.000 abstract description 3
- 230000003014 reinforcing effect Effects 0.000 abstract description 3
- 238000005303 weighing Methods 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 51
- 210000004027 cell Anatomy 0.000 description 22
- 230000000694 effects Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 241000287828 Gallus gallus Species 0.000 description 10
- 241000209094 Oryza Species 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 210000002540 macrophage Anatomy 0.000 description 10
- 108010062580 Concanavalin A Proteins 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 238000005534 hematocrit Methods 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000002949 hemolytic effect Effects 0.000 description 7
- 230000000242 pagocytic effect Effects 0.000 description 7
- 210000003371 toe Anatomy 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- 230000007815 allergy Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 206010013786 Dry skin Diseases 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000976 ink Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 235000021552 granulated sugar Nutrition 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 230000007365 immunoregulation Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000003024 peritoneal macrophage Anatomy 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- YHVQIDWAIRCSOQ-UHFFFAOYSA-N 1-nitrotetrazol-2-ium chloride Chemical compound [Cl-].[O-][N+](=O)N1C=[NH+]N=N1 YHVQIDWAIRCSOQ-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000167880 Hirundinidae Species 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- WIPCMBDEWMKHCR-UHFFFAOYSA-N dimethyl sulfate;phenazine Chemical compound COS(=O)(=O)OC.C1=CC=CC2=NC3=CC=CC=C3N=C21 WIPCMBDEWMKHCR-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229950006238 nadide Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- -1 YAC- 1 cell Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种免疫调节冲剂及制备方法,它由一定比例党参、茯苓、莲子、山药、炒麦芽、谷芽、鸡内金、芦根、薏苡仁组成,步骤是:A、按比例称取党参、茯苓、莲子、山药、炒麦芽、谷芽、鸡内金、芦根、薏苡仁中药饮片,第一次加3-4倍水煎煮,滤过,得滤液A;B、药渣第二次加2-3倍水煎煮,滤过,得滤液B;C、药渣第三次加1.2-2倍水煎煮,滤过,得滤液C,合并三次滤液,静置,取上清液,浓缩成流浸膏,加一倍量乙醇,搅拌均匀,静置,滤取上清液,减压,回收乙醇,浓缩成稠膏,加入蔗糖粉制粒,干燥,得调节冲剂。配方合理,使用方便,方法易行,操作简便,携带使用方便,不含性激素的中药,适合儿童服用,同时还能健脾消食。
Description
技术领域
本发明属于功能食品饮料领域,更具体涉及一种免疫调节冲剂,同时还涉及一种免疫调节冲剂的制备方法。
背景技术
目前市场上涉及免疫调节冲剂很多,涉及免疫调节的原料多采用营养补充剂,微生物、肽、蛋白质、脂肪、碳水化合物,也有在传统食物中添加具有相应功能的物质,如活性成分、药食同源中药等,存在数量多,调节免疫效果有限等缺点。
发明内容
本发明的目的是在于提供了一种免疫调节冲剂,配方合理,使用方便,具有良好的免疫调节作用且携带使用方便。
本发明的另一个目的是在于提供了一种免疫调节冲剂的制备方法,方法易行,操作简便,制备的呈固体颗粒状,用时用水冲服,携带使用方便;处方中含有党参、茯苓、莲子、山药、炒麦芽、谷芽、鸡内金、芦根、薏苡仁九种天然药物,属于天然健康食品;处方中不含性激素的中药,适合儿童服用,同时还能健脾消食。
为了实现上述的目的,本发明采用以下技术措施:
其技术构思是:以党参、茯苓、莲子、山药、炒麦芽、谷芽、鸡内金、芦根、薏苡仁为原料,研制了一种具有良好的免疫调节作用且携带使用方便并适合儿童患者饮用的复合保健饮料。经动物实验表明:小鼠的血清溶血素半数溶血值(HC50)和抗体生成细胞数在各剂量组与对照组间比较均有显著性差异(P<0.05,P<0.01);巨噬细胞吞噬鸡红细胞能力和NK细胞活性在中、高剂量组与对照组间比较均有显著性差异(P<0.05);单核-巨噬细胞碳廓清能力在低剂量组与对照组之间比较有显著性差异(P<0.05);胸腺/体重比值在高剂量组与对照组间比较有显著性差异(P<0.05)。本次实验未见到本免疫调节冲剂对小鼠体重增长值、脾脏/体重比值、迟发型变态反应、淋巴细胞增值能力的影响。
一种免疫调节冲剂,它由以下重量份的原料制成:
一种免疫调节冲剂,它由以下重量份的原料制成(优选范围):
一种免疫调节冲剂,它由以下重量份的原料制成(较好范围):
一种免疫调节冲剂,它由以下重量份的原料制成(最好范围):
一种免疫调节冲剂,它由以下重量份的原料制成:
上述十种原料,最关键的是以党参、茯苓、莲子、山药为君药,辅以炒麦芽、谷芽、鸡内金、芦根、薏苡仁。党参为桔梗科党参属,多年生草本植物,有乳汁。党参为中国常用的传统补益药,古代以山西上党地区出产的党参为上品,具有补中益气,健脾益肺之功效。党参有增强免疫力、扩张血管、降压、改善微循环、增强造血功能等作用。此外对化疗放疗引起的白细胞下降有提升作用。茯苓具有利水渗湿,健脾,宁心。用于水肿尿少,痰饮眩悸,脾虚食少,便溏泄泻,心神不安,惊悸失眠。莲子具有补脾止泻,止带,益肾涩精,养心安神的功能,用于脾虚泄泻,带下,遗精,心悸失眠。山药具有补脾养胃,生津益肺,补肾涩精的功能。用于脾虚食少,久泻不止,肺虚喘咳,肾虚遗精,带下,尿频,虚热消渴。麸炒山药补脾健胃。用于脾虚食少,泄泻便溏,白带过多。按照中医传统理论,本发明组方制得的冲剂可调节脾胃功能,健脾消湿,再补中益气,可以提高机体免疫力。与现有技术对比,具有不断可以提高免疫力,而且处方中不含性激素的中药,适合儿童服用,同时还能健脾消食。
一种免疫调节冲剂的制备方法,其步骤是:
A、按比例称取党参、茯苓、莲子、山药、炒麦芽、谷芽、鸡内金、芦根、薏苡仁九味中药饮片,第一次加药材量3-4倍水煎煮2小时左右,滤过,得滤液A;
B、将步骤A药渣第二次加药材量2-3倍水煎煮1.5小时左右,滤过,得滤液B;
C、将步骤B药渣第三次加药材量1.2-2倍水煎煮1.5小时左右,滤过,得滤液C,合并三次滤液,静置,取上清液,浓缩成流浸膏,加一倍量乙醇,搅拌均匀,静置12小时以上,30小时以下,滤取上清液,减压(压力是-0.08MPa左右)回收乙醇,浓缩成稠膏,相对密度为1.25-1.30,加入适量(80-95%)的白砂糖制粒(现有技术),65-70℃干燥(2h-3h),即得一种免疫调节冲剂。
通过上述三个步骤的技术措施:最关键的是C步骤,主要解决了中药浸膏难于干燥的难题,主要达到了节省干燥时间的技术效果,其发明相对于现有技术的进步用一倍量乙醇,搅拌均匀,静置12小时以上,30小时以下,滤取上清液,减压(压力是0.08MPa左右)回收乙醇,浓缩成稠膏,相对密度为1.25-1.30,加入适量(80-95%)的蔗糖粉制粒(现有技术),65-70℃干燥(2h-3h),即得;技术方案与现有技术的主要区别在大多采用水制粒,而本发明采用流浸膏制粒。
本发明与现有技术相比,具有以下优点和效果:
本发明的目的是提供了一种免疫调节冲剂及其制备方法,其配方合理,使用方便,具有良好的免疫调节作用且携带使用方便。本发明的另一个目的是在于提供了一种免疫调节冲剂及其制备方法的制备方法,方法易行,操作简便,制备的呈固体颗粒状,用时用水冲服,携带使用方便;处方中含有党参、茯苓、莲子、山药、炒麦芽、谷芽、鸡内金、芦根、薏苡仁九种天然药物,属于天然健康食品;处方中不含性激素的中药,适合儿童服用,同时还能健脾消食。
具体实施方式
实施例1:
一种免疫调节冲剂,它由以下重量份的原料制成:
一种免疫调节冲剂的制备方法,其步骤是:
A、按比例称取党参、茯苓、莲子、山药、炒麦芽、谷芽、鸡内金、芦根、薏苡仁九味中药饮片,第一次加药材量3或4倍水煎煮2小时左右,滤过,得滤液A;
B、将步骤A药渣第二次加药材量2或3倍水煎煮1.5小时左右,滤过,得滤液B;
C、将步骤B药渣第三次加药材量1.2或1.5或1.8或2倍水煎煮1.5小时左右,滤过,得滤液C,合并三次滤液,静置,取上清液,浓缩成流浸膏,加一倍量乙醇,搅拌均匀,静置12小时以上,30小时以下,滤取上清液,减压(压力-0.08MPa左右)回收乙醇,浓缩成稠膏,加入适量(80-95%)的白砂糖制粒(现有技术),65或67或79或70℃干燥(2h-3h),获得一种免疫调节冲剂。
实施例2-6:
原料及实施例 | 2 | 3 | 4 | 5 | 6 |
党参 | 8 | 10 | 12 | 13 | 15 |
茯苓 | 10 | 9 | 8 | 7 | 5 |
莲子 | 9 | 8 | 7 | 10 | 6 |
山药 | 14 | 12 | 11 | 8 | 9 |
炒麦芽 | 20 | 18 | 15 | 14 | 12 |
谷芽 | 12 | 14 | 13 | 16 | 18 |
鸡内金 | 1 | 2 | 3 | 5 | 4 |
芦根 | 13 | 15 | 16 | 17 | 20 |
薏苡仁 | 20 | 15 | 14 | 13 | 12 |
白砂糖 | 95 | 100 | 86 | 90 | 85 |
其制备方法与实施例1相同。
通过上述的的技术措施,获得一种免疫调节冲剂。
用本发明组方和工艺制得的免疫调节冲剂,进行如下药理实验:
1.1实验动物:
选用中国药品生物制品检定所实验动物中心(批准证号:2000第017号)繁殖的Ba1B/c健康雄性小鼠48只,体重18-22g,分为4组,每组12只,作为免疫一组,进行脏器/体重比值、迟发型变态反应、半数溶血值(HC50)的测定、小鼠腹腔巨噬细胞吞噬鸡红细胞实验和抗体生成细胞检测;昆明健康雌性小鼠60只,体重18-22g,分为4组,每组15只,作为免疫二组,进行碳廓清实验;Ba1B/c健康雄性小鼠48只,体重18-22g,分为4组,每组12只,作为免疫三组,进行ConA诱导的小鼠淋巴细胞转化实验和NK细胞活性测定实验。
1.2剂量选择:
本免疫调节冲剂按人体推荐量为每人(成人)每日2次,每次1袋,总量为16g/60kg体重。本实验设计了高、中、低三个剂量组,即小鼠每只经口灌胃分别给予本免疫调节冲剂8.0g/kg.bw、2.7g/kg.bw和0.8g/kg.bw,分别相当于人体推荐用量的30倍、10倍和3倍,将本免疫调节冲剂用水稀释配制成高、中、低剂量浓度进行灌胃,对照组直接以蒸馏水灌胃,灌胃量为0.4ml/20g.bw。连续给予受试物26天后活杀小鼠并测定各项免疫指标。
1.3仪器与试剂:
动物天平、分析天平、洁净工作台、二氧化碳培养箱、离心机、恒温水浴、酶标仪、显微镜等。
无菌手术器械、游标卡尺(精密度0.01mm)、微量注射器(25μl)、细胞计数器、24孔和96孔平底细胞培养板、96孔U型细胞培养板、玻璃平皿、纱布、试管、玻片架、200目筛网、计时器、血色素吸管、载玻片等。
绵羊红细胞(SRBC)、生理盐水、Hank's液(pH7.2)、RPMI1640培养液、小牛血清、青链霉素、刀豆蛋白A(ConA)、1%冰醋酸、1mol/L的HCL溶液、酸性异丙醇(96m1异丙醇加4ml1mol/L的HCL溶液)、MTT、PBS缓冲液(pH7.2-7.4)、补体(豚鼠血清)、SA缓冲液、琼脂糖、YAC-1细胞、乳酸钠、硝基氯化四氮唑、吩嗪二甲酯硫酸盐、氧化型辅酶I、0.2mol/L的Tris-HCL缓冲液(pH8.2)、1%NP40、印度墨汁、0.1%Na2CO3、Giemsa染液等。
1.4实验方法:
1.4.1脏器/体重比值测定
小鼠称重后脱臼处死,取脾脏和胸腺,去尽筋膜,用滤纸吸干脏器表面血污,称重,计算脾脏/体重比值和胸腺/体重比值。
1.4.2迟发型变态反应(足趾增厚法)(DTH)
取羊血,生理盐水洗涤3次,每只鼠经腹腔注射2%(v/v,用生理盐水配制)压积SRBC(2000rpm,10分钟)0.2ml,致敏后4天,测量左后足趾部厚度,同一部位测量两次,取平均值。然后在测量部位皮下注射20%(v/v,用生理盐水配制)压积SRBC20μl,于注射后24小时测量左后足趾部厚度,以攻击前后足趾厚度的差值(足趾肿胀度)来表示DTH的程度。1.4.3ConA诱导的小鼠淋巴细胞转化实验(MTT法)
将小鼠处死,在75%酒精的烧杯中灭菌10分钟后,无菌取脾,置于高压灭菌后装有3cmx3cm四层纱布的小平皿中,加入适量无菌Hank's液,用纱布将脾包住,用弯头镊子经轻将脾磨碎,制成单细胞悬液,用Hank's液洗三次,每次离心10分钟(1000rpm)。然后将细胞悬浮于2ml的完全培养液中,计数活细胞数,调整细胞浓度为2×106个/ml。再将细胞悬液分两孔加入24孔培养板中,每孔1ml,在其中一孔加50μl ConA液(相当于5μl/ml),另一孔作为对照,置5%CO2,37℃培养72小时。培养结束前4小时,每孔轻轻吸去上清液0.7ml,加入0.7ml不含小牛血清的RPMI1640培养液,同时加入MTT(5mg/m1)50μl/孔,继续培养4小时。培养结束后,每孔加入1ml酸性异丙醇,吹打混匀,使紫色结晶完全溶解。然后移入比色杯中,在721分光光度计上比色测定,波长为570nm.淋巴细胞的增值能力用加ConA孔的光密度值减去不加ConA孔的光密度值表示。
1.4.4抗体生成细胞检测(Jerme改良玻片法)
取羊血,生理盐水洗涤3次,每只鼠经腹腔注射2%(v/v,用生理盐水配制)压积SRBC 0.2ml。将SRBC免疫4天后的小鼠处死,取脾,制成细胞悬液。将琼脂糖加热溶解后,与等量双倍Hank's液混合,分装小试管,每管0.5ml,再向管内加10%(v/v,用SA液配制)压积SRBC 50μl,脾细胞悬液20μl,迅速混匀后,倾倒于已刷琼脂糖薄层的玻片上,待琼脂凝固后,将玻片水平扣放在片架上,放入二氧化碳培养箱中孵育1.5小时,然后用SA缓冲液稀释的补体(1:10)加入到玻片架凹槽内,继续孵育1.5小时,计数溶血空斑数。
1.4.5血清溶血素半数溶血值(HC50)的测定
取羊血,生理盐水洗涤3次,,每只鼠经腹腔注射2%(v/v,用生理盐水配制)压积SRBC 0.2ml。4天后,摘除眼球取血于1.5ml离心管内,放置约1小时,使血清充分析出,2000rmp离心10分钟,收集血清。用SA缓冲液将血清稀释为200倍,取1m1于试管内,依次加入10%(v/v,用SA液配制)压积SRBC 0.5ml,补体1ml(用SA液按1:7稀释)。另设不加血清的对照管(用SA液替代)。置37℃恒温水浴中保温30分钟后,冰浴终止反应。2000rpm离心10分钟,取上清1ml,加都氏试剂3ml。同时取10%(v/v,用SA液配制)压积SRBC 0.25ml,加都氏试剂至4ml于另一个试管中。充分混匀,放置10分钟后,于540nm处以对照管作空白,在721分光光度计上分别测定各管光密度值。溶血素的量以半数溶血值(HC50)表示,按下式计算。
样品HC50=样品光密度值/SRBC半数溶血时的光密度值×稀释倍数
1.4.6小鼠碳廊清实验
小鼠尾静脉注射1:4稀释的印度墨汁,待墨汁注入,立即计时。注入墨汁10分钟前后,分别从内眦静脉丛取血20μl,并将其加到2mL的Na2CO3溶液中,用721分光光度计在600nm波长处测光密度值(0D),以Na2CO3溶液作为空白对照。将小鼠处死,取肝脏和脾脏称重。按下式计算吞噬指数a:k=(lg0D1-lg0D2)/(t2-t1)a=体重÷(肝脏+脾脏)×3√k
1.4.7小鼠腹腔巨噬细胞巨噬鸡红细胞实验(半体内法)
小鼠腹腔注射5ml Hank's液,轻轻按摩小鼠腹部,10分钟后颈椎脱臼处死小鼠,分别取腹腔巨噬细胞洗液0.5ml,滴于两片载玻片上,立即加入等量的1%压积鸡红细胞悬液,充分混匀,放入垫有湿纱布的搪瓷盒内,移置37℃孵箱孵育30分钟,孵毕,于生理盐水中漂洗,以除去未贴片细胞。晾干,以甲醇固定,4%(v/v)Giemsa磷酸缓冲液染色,再用蒸馏水漂洗晾干。每片计数100个巨噬细胞,按下式计算吞噬率和吞噬指数:
吞噬率%=吞噬鸡红细胞的巨噬细胞数/计数的巨噬细胞数×100
吞噬指数=被吞噬的鸡红细胞总数/计数的巨噬细胞数
1.4.8NK细胞活性测定(乳酸脱氢酶LDH测定法)
实验前24小时将靶细胞YAC-1进行传代培养,应用前以Hank's液洗3次,用含10%小牛血清的RPMI 1640完全培养液调整细胞浓度为1×10个/ml。受试小鼠拉颈处死,无菌取脾,制成脾细胞悬液,用Hank's液洗3次,1500rpm离心10分钟,在用2ml含10%小牛血清的RPMI 1640完全培养液重悬,用台酚兰染色计数(活细胞数应在95%以上),调整细胞浓度为5×106个/ml,使效靶比为50:1。取靶细胞和效应细胞各100μl,加入U形96孔培养板中,靶细胞自然释放孔加靶细胞和培养液各100μl,靶细胞最大释放孔家靶细胞和1%NP40各100μl,上述各项均设三个平行孔,37℃,5%CO2培养箱中培养4小时,将96孔以1500rpm离心5分钟,每孔吸取上清100μl置酶标板中,加入LDH基质液100μl,反应10分钟,然后每孔加入1ml的HC1溶液30μl终止反应,在酶标仪490nm处测OD值。NK活性按下式计算
LDH基质液的配制:乳酸钠5×10-2mo1/L
硝基氯化四氮唑6.6×10-4mol/L
吩嗪二甲酯硫酸盐2.8×10-4mol/L
氧化型辅酶I 1.3×10-3mol/L
将上述试剂溶于0.2mo1/L的Tris-HCl缓冲液中(Ph8.2)
1.5实验数据用SPSS10.0软件进行方差分析。
2结果
2.1本免疫调节冲剂对小鼠体重的影响
表1各组小鼠的初始体重
由表1可见,经统计学处理,小鼠的初始体重在低、中、高剂量组与对照组间比较均无显著性差异(P>0.05),即小鼠的初始体重在各组间较为均衡。
表2本免疫调节冲剂对小鼠体重的影响
由表2可见,经口给予小鼠不同剂量的本免疫调节冲剂26天,经统计学处理,小鼠的体重增长值在各剂量组与对照组间比较均未有统计学上的差异(P>0.05)。
2.2本免疫调节冲剂对小鼠脏器/体重比值的影响
表3本免疫调节冲剂对小鼠脏器/体重比值的影响
与对照组比较:*P<0.05
由表3可见,经口给予小鼠不同剂量的本免疫调节冲剂26天,经统计学处理,其脾脏/体重比值、在各剂量组与对照组间比较均无显著性差异(P>0.05);胸腺/体重比值在高剂量组与对照组间比较有显著性差异(P<0.05)。
2.3本免疫调节冲剂对小鼠细胞免疫功能的影响
2.3.1本免疫调节冲剂对小鼠迟发型变态反应(DTH)的影响
表4本免疫调节冲剂对小鼠迟发型变态反应(DTH)的影响
剂量浓度(g/kg.bw) | 动物数(只) | 足趾肿胀度(mm) | P值 |
0.0 | 12 | 0.34±0.089 | |
0.8 | 12 | 0.28±0.113 | 0.078 |
2.7 | 12 | 0.35±0.091 | 0.929 |
8.0 | 12 | 0.31±0.069 | 0.402 |
由表4可见,经口给予小鼠不同剂量的本免疫调节冲剂26天,经统计学处理,其足趾肿胀度在各剂量组与对照组间比较均未有显著性差异(P>0.05)。
2.3.2本免疫调节冲剂对(ConA)诱导的小鼠淋巴细胞转化实验的影响
表5本免疫调节冲剂对(ConA)诱导的小鼠淋巴细胞转化实验的影响
剂量浓度(g/kg.bw) | 动物数(只) | 淋巴细胞增殖能力(OD差值) | P值 |
0.0 | 12 | 0.49±0.121 | |
0.8 | 12 | 0.42±0.135 | 0.151 |
2.7 | 12 | 0.46±0.059 | 0.607 |
8.0 | 12 | 0.46±0.098 | 0.540 |
由表5可见,经口给予小鼠不同剂量的本免疫调节冲剂26天,经统计学处理,其淋巴细胞的增值能力在各剂量组与对照组间比较均未有显著性差异(P>0.05)。
2.4本免疫调节冲剂对体液免疫的影响
2.4.1本免疫调节冲剂对抗体生成细胞数的影响
表6本免疫调节冲剂对抗体生成细胞数的影响
剂量浓度(g/kg.bw) | 动物数(只) | 溶血空斑数(×10<sup>3</sup>全脾) | P值 |
0.0 | 11 | 13.6±6.87 | |
0.8 | 12 | 20.4±7.36<sup>*</sup> | 0.015 |
2.7 | 10 | 22.6±6.65<sup>**</sup> | 0.002 |
8.0 | 12 | 20.8±4.23<sup>*</sup> | 0.010 |
与对照组比较:**P<0.01
*P<0.05
由表6可见,经口给予小鼠不同剂量的本免疫调节冲剂26天,经统计学处理,其抗体生成细胞数在各剂量组与对照组间比较均有显著性差异(P<0.05,P<0.01)。
2.4.2本免疫调节冲剂对小鼠半数溶血值(HC50)的影响
表7本免疫调节冲剂对小鼠半数溶血值(HC50)的影响
剂量浓度(g/kg.bw) | 动物数(只) | HC50 | P值 |
0.0 | 11 | 86.49±31.5 | |
0.8 | 12 | 146.1±41.1<sup>**</sup> | 0.000 |
2.7 | 10 | 195.0±32.0<sup>**</sup> | 0.000 |
8.0 | 12 | 234.0±28.3<sup>**</sup> | 0.000 |
与对照组比较:**P<0.01
由表7可见,经口给予小鼠不同剂量的本免疫调节冲剂26天,经统计学处理,其半数溶血值(HC50)在各剂量组与对照组间比较均有极显著性差异(P<0.01)。
2.5本免疫调节冲剂对小鼠单核-巨噬细胞吞噬功能的影响
2.5.1本免疫调节冲剂对小鼠单核-巨噬细胞碳廓清能力的影响
表8本免疫调节冲剂对小鼠单核-巨噬细胞碳廓清能力的影响
与对照组比较:*P<0.05
由表8可见,经口给予小鼠不同剂量的本免疫调节冲剂26天,经统计学处理,其碳廓清功能在低剂量组与对照组间比较有显著性差异(P<0.05)。
2.5.2本免疫调节冲剂对小鼠巨噬细胞吞噬鸡红细胞能力影响
表9本免疫调节冲剂对小鼠巨噬细胞吞噬鸡红细胞能力影响
与对照组比较:*P<0.05
由表9可见,经口给予小鼠不同剂量的本免疫调节冲剂26天,经统计学处理,其吞噬率和吞噬指数在中、高剂量组与对照组间比较均有显著性差异(P<0.05)。
2.6本免疫调节冲剂对小鼠Nk细胞活性的影响
表10本免疫调节冲剂对小鼠NK细胞活性的影响
剂量浓度(g/kg.bw) | 动物数(只) | NK细胞活性(%) | P值 |
0.0 | 12 | 47.1±8.63 | |
0.8 | 12 | 52.3±13.8 | 0.344 |
2.7 | 12 | 60.3±17.8* | 0.020 |
8.0 | 12 | 60.5±11.6* | 0.018 |
与对照组比较:*P<0.05
由表10可见,经口给予小鼠不同剂量的本免疫调节冲剂26天,经统计学处理,其NK细胞活性在中、高剂量组与对照组间比较有显著性差异(P<0.05)。
3小结
经口给予小鼠不同剂量的本免疫调节冲剂26天,经统计学处理,小鼠的血清溶血素半数溶血值(HC50)和抗体生成细胞数在各剂量组与对照组间比较均有显著性差异(P<0.05,P<0.01);巨噬细胞吞噬鸡红细胞能力和NK细胞活性在中、高剂量组与对照组间比较均有显著性差异(P<0.05);单核-巨噬细胞碳廓清能力在低剂量组与对照组之间比较有显著性差异(P<0.05);胸腺/体重比值在高剂量组与对照组间比较有显著性差异(P<0.05)。本次实验未见到本免疫调节冲剂对小鼠体重增长值、脾脏/体重比值、迟发型变态反应、淋巴细胞增殖能力的影响。
实施例2:
一种免疫调节冲剂及其制备方法,它由以下质量百分数的原料制成:
一种免疫调节冲剂及其制备方法的制备方法,其步骤是:
A、按上述配方称量党参、茯苓、莲子、山药、炒麦芽、谷芽、鸡内金、芦根、薏苡仁九味中药饮片,第一次加药材量3~4倍水煎煮2小时,滤过,得滤液A;
B、药渣第二次加药材量2~3倍水煎煮1.5小时,滤过,得滤液B;
C、药渣第三次加药材量1.2~2倍水煎煮1.5小时,滤过,得滤液C,合并三次滤液,静置,取上清液,浓缩成流浸膏,加一倍量乙醇,搅拌均匀,静置12小时以上,滤取上清液,减压回收乙醇,浓缩成稠膏,加入适量的蔗糖粉制粒,65~70℃干燥,即得。
实施例3:
一种免疫调节冲剂及其制备方法,它由以下质量百分数的原料制成:
一种免疫调节冲剂及其制备方法的制备方法,其步骤是:
A、按上述配方称量党参、茯苓、莲子、山药、炒麦芽、谷芽、鸡内金、芦根、薏苡仁九味中药饮片,第一次加药材量3~4倍水煎煮2小时,滤过,得滤液A;
B、药渣第二次加药材量2~3倍水煎煮1.5小时,滤过,得滤液B;
C、药渣第三次加药材量1.2~2倍水煎煮1.5小时,滤过,得滤液C,合并三次滤液,静置,取上清液,浓缩成流浸膏,加一倍量乙醇,搅拌均匀,静置12小时以上,滤取上清液,减压回收乙醇,浓缩成稠膏,加入适量的蔗糖粉制粒,65~70℃干燥,即得。
实施例4:
一种免疫调节冲剂及其制备方法,它由以下质量百分数的原料制成:
一种免疫调节冲剂及其制备方法的制备方法,其步骤是:
A、按上述配方称量党参、茯苓、莲子、山药、炒麦芽、谷芽、鸡内金、芦根、薏苡仁九味中药饮片,第一次加药材量3~4倍水煎煮2小时,滤过,得滤液A;
B、药渣第二次加药材量2~3倍水煎煮1.5小时,滤过,得滤液B;
C、药渣第三次加药材量1.2~2倍水煎煮1.5小时,滤过,得滤液C,合并三次滤液,静置,取上清液,浓缩成流浸膏,加一倍量乙醇,搅拌均匀,静置12小时以上,滤取上清液,减压回收乙醇,浓缩成稠膏,加入适量的蔗糖粉制粒,65~70℃干燥,即得。
Claims (7)
1.一种免疫调节冲剂,它由以下重量份的原料制成:
2.根据权利要求1所述的一种免疫调节冲剂,其特征在于:
3.根据权利要求1所述的一种免疫调节冲剂,其特征在于:
4.根据权利要求1所述的一种免疫调节冲剂,其特征在于:
5.根据权利要求1所述的一种免疫调节冲剂,其特征在于:
6.根据权利要求1所述的一种免疫调节冲剂,其特征在于:
7.权利要求1所述的一种免疫调节冲剂的制备方法,其步骤是:
A、按比例称取党参、茯苓、莲子、山药、炒麦芽、谷芽、鸡内金、芦根、薏苡仁九味中药饮片,第一次加药材量3-4倍水煎煮2小时,滤过,得滤液A;
B、药渣第二次加药材量2-3倍水煎煮1.5小时,滤过,得滤液B;
C、药渣第三次加药材量1.2-2倍水煎煮1.5小时,滤过,得滤液C,合并三次滤液,静置,取上清液,浓缩成流浸膏,加一倍量乙醇,搅拌均匀,静置12小时,30小时以下,滤取上清液,减压:压力是-0.08MPa,回收乙醇,浓缩成稠膏,相对密度为1.25-1.30,加入80-95%的白砂糖制粒,65-70℃干燥2h-3h,得一种免疫调节冲剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910309522.2A CN110179937A (zh) | 2019-04-17 | 2019-04-17 | 一种免疫调节冲剂及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910309522.2A CN110179937A (zh) | 2019-04-17 | 2019-04-17 | 一种免疫调节冲剂及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110179937A true CN110179937A (zh) | 2019-08-30 |
Family
ID=67714674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910309522.2A Pending CN110179937A (zh) | 2019-04-17 | 2019-04-17 | 一种免疫调节冲剂及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110179937A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117379515A (zh) * | 2023-11-30 | 2024-01-12 | 江西草珊瑚药业有限公司 | 一种促进睡眠增强免疫力的膏剂及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1221615A (zh) * | 1997-12-30 | 1999-07-07 | 陈辉 | 清明五疳健胃消食冲剂 |
-
2019
- 2019-04-17 CN CN201910309522.2A patent/CN110179937A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1221615A (zh) * | 1997-12-30 | 1999-07-07 | 陈辉 | 清明五疳健胃消食冲剂 |
Non-Patent Citations (2)
Title |
---|
芝麻茶馆: ""清明冲剂"", 《HTTP://BBS.MEIJIANPIN.COM/HX/P15479/》 * |
高兴: ""【用植堂】脾牛清明冲剂"", 《HTTP://BLOG.SINA.CN/DPOOL/BLOG/S/BLOG_70D57B4F0102XHL7.HTML?VT=4》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117379515A (zh) * | 2023-11-30 | 2024-01-12 | 江西草珊瑚药业有限公司 | 一种促进睡眠增强免疫力的膏剂及其制备方法 |
CN117379515B (zh) * | 2023-11-30 | 2024-05-07 | 江西草珊瑚药业有限公司 | 一种增强免疫力的膏剂及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101095751B (zh) | 具有祛黄褐斑、改善营养性贫血的药物组合物及制备方法 | |
CN102526477B (zh) | 一种增强免疫力的药物组合物及其制备方法和应用 | |
CN105532998A (zh) | 一种含有蛹虫草的保健茶及其制备方法 | |
CN105169105A (zh) | 具有抗肿瘤、滋阴养胃、增强免疫力功能的中药制剂及其制备方法 | |
CN109007514A (zh) | 一种具有提高免疫力功能的组合物及其制备方法 | |
CN101461918B (zh) | 一种治疗男性更年期综合症及延缓衰老的药物组合物 | |
CN105055855B (zh) | 具有改善睡眠、增强免疫力作用的中药组合物及其制备方法和应用 | |
CN104667197A (zh) | 一种增强免疫力的组合物及其制备方法和应用 | |
CN110179937A (zh) | 一种免疫调节冲剂及制备方法 | |
CN102754833B (zh) | 增强免疫力的保健品及其制备方法 | |
CN105535425B (zh) | 一种具有增强免疫力作用的中药组合物及其制备方法与用途 | |
CN101461894B (zh) | 一种治疗女性更年期综合症及延缓衰老的药物组合物 | |
CN107156830A (zh) | 一种增强免疫力的组合物、其制备方法和应用 | |
CN102631494B (zh) | 一种提高免疫力、抗疲劳的中药组合物 | |
CN101366860B (zh) | 用于利眠袪斑的胶玫口服液 | |
CN103735621B (zh) | 一种具有降血脂和增强免疫力作用的中药组合物 | |
CN105815786A (zh) | 一种双花黄精片剂及其制备方法 | |
CN102406172B (zh) | 增强免疫力的保健食品及其制备方法 | |
CN102475201A (zh) | 一种具有保健功能的蛋白粉组合物 | |
CN106177014A (zh) | 一种增强免疫力的蛹虫草颗粒及其制备方法 | |
CN105838560B (zh) | 一种艾叶保健酒及其制备方法 | |
CN104189038A (zh) | 用于调理女性生理健康和免疫功能的中药制剂 | |
CN107019745A (zh) | 一种具有增强免疫力功能的组合物及其制备方法 | |
CN109757629A (zh) | 一种复合雪莲果液体饮食组合物及其制备和使用方法 | |
CN105796884A (zh) | 一种虫草阿胶片剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190830 |